Last reviewed 2026-05-23 · How we verify

Dbcamp (BUCLADESINE)

Phase 2 active Small molecule ✓ Verified May 2026 Quality 24/100

Dbcamp (generic name: BUCLADESINE) is a bucladesine drug. It is currently in Phase 2 development.

Dbcamp works by increasing levels of cyclic AMP (cAMP) in the body, which helps to relax smooth muscle and improve blood flow.

Dbcamp (BUCLADESINE) is a small molecule drug in the bucladesine class, originally developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are unknown, but it is believed to work by increasing the levels of cyclic AMP (cAMP) in the body, which can help to relax smooth muscle and improve blood flow. The commercial status of Dbcamp is unclear, and it is not known whether it is FDA-approved or off-patent. Further research is needed to determine its potential uses and safety profile.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BUCLADESINE
Drug class	bucladesine
Modality	Small molecule
Therapeutic area	Hematology
Phase	Phase 2

Mechanism of action

Think of cAMP like a messenger that helps to relax muscles and improve blood flow. When cAMP levels are low, muscles can become stiff and blood flow can be restricted. Dbcamp helps to increase cAMP levels, which can help to improve blood flow and reduce muscle stiffness.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dbcamp CI brief — competitive landscape report
Dbcamp updates RSS · CI watch RSS

Frequently asked questions about Dbcamp

What is Dbcamp?

Dbcamp (BUCLADESINE) is a bucladesine drug.

How does Dbcamp work?

Dbcamp works by increasing levels of cyclic AMP (cAMP) in the body, which helps to relax smooth muscle and improve blood flow.

What is the generic name of Dbcamp?

BUCLADESINE is the generic (nonproprietary) name of Dbcamp.

What drug class is Dbcamp in?

Dbcamp belongs to the bucladesine class. See all bucladesine drugs at /class/bucladesine.

What development phase is Dbcamp in?

Dbcamp is in Phase 2.

Drug class: All bucladesine drugs
Therapeutic area: All drugs in Hematology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing